The Pharmacokinetics and Extracorporeal Elimination of Bongkrekic Acid during Blood Purification Therapies: A Case Study

Shebl Radwan*

Department of Management Information Systems, College of Business and Economics, Qassim University, Saudi Arabia

Abstract

Bongkrekic acid (BA) is a potent mitochondrial toxin produced by Burkholderia gladioli that poses severe health risks to humans upon ingestion. Its mechanism of toxicity involves inhibition of mitochondrial ATP transport, leading to metabolic acidosis and multi-organ failure. Management of BA poisoning remains challenging due to limited treatment options and rapid onset of toxicity. This case study explores the pharmacokinetics of BA and its elimination via blood purifcation therapies, including hemodialysis and hemoperfusion. A patient presenting with BA poisoning following ingestion of contaminated food was managed in the intensive care unit with supportive care and timely initiation of blood purifcation therapies. Pharmacokinetic monitoring revealed the efectiveness of these therapies in reducing BA levels and improving clinical outcomes, highlighting their role in enhancing toxin clearance. The case underscores the importance of early recognition, prompt intervention, and pharmacokinetic assessment in managing severe BA poisoning to mitigate adverse outcomes and improve patient survival.

K **:** Bongkrekic acid; Mitochondrial toxin; Blood puri cation; Hemodialysis; Hemoperfusion; Pharmacokinetics

I c

Bongkrekic acid (BA) is a potent toxin produced by Burkholderia gladioli, primarily known for its devastating e ects on human health when ingested. is compound targets mitochondrial function by inhibiting the adenine nucleotide translocase, disrupting ATP transport and leading to severe metabolic acidosis and organ failure [1,2]. Due to its high toxicity and limited treatment options, BA poisoning presents signi cant challenges in clinical management. e management of BA poisoning o en involves supportive care and, in severe cases, blood puri cation therapies such as hemodialysis and hemoperfusion [3,4].

ese therapies aim to enhance toxin elimination by removing BA from circulation, thereby reducing systemic toxicity and improving clinical outcomes. Understanding the pharmacokinetics of BA, including its distribution, metabolism, and elimination during blood puri cation therapies, is crucial for optimizing treatment strategies and improving patient survival. is case study explores the pharmacokinetic pro le of BA in a patient presenting with acute poisoning following ingestion of contaminated food [5,6]. It focuses on the e cacy of blood puri cation therapies in enhancing BA clearance and managing associated complications. e insights gained from this case underscore the importance of early recognition, prompt intervention, and tailored therapeutic approaches in mitigating the e ects of BA poisoning and improving patient outcomes. Bongkrekic acid (BA) is a highly toxic mitochondrial poison produced by certain strains of bacteria, notably Burkholderia gladioli. It is known for its lethal e ects on humans and animals when ingested or exposed through contaminated food sources [7,8]. e toxicity of BA stems from its ability to inhibit the mitochondrial adenine nucleotide translocase, a critical enzyme involved in ATP transport across mitochondrial membranes. is disruption leads to cellular energy depletion and can result in severe metabolic acidosis, multi-organ failure, and o en fatal outcomes.

e management of BA poisoning presents signi cant challenges due to its rapid onset of toxicity and limited treatment options. In cases where BA poisoning is suspected, early recognition and supportive care are crucial. Blood puri cation therapies, such as hemodialysis and hemoperfusion, have been explored as potential interventions to enhance BA elimination and improve patient outcomes. is article

metabolic acidosis.

**H : Hemoperfusion involves the passage of blood through adsorbent materials, such as activated charcoal or resin-based columns, which selectively bind toxins like BA. is method o ers a complementary approach to hemodialysis and can enhance toxin removal, particularly for highly protein-bound substances.

C a ac a (CRRT): CRRT provides continuous, slow, and prolonged removal of toxins from the bloodstream, making it suitable for critically ill patients with compromised hemodynamic stability. While less commonly used for BA poisoning, CRRT may be considered in cases requiring prolonged toxin clearance.

Ca a

is article presents a detailed case study of a patient admitted to the intensive care unit (ICU) following ingestion of food contaminated with BA. e patient presented with acute gastrointestinal symptoms, metabolic acidosis, and evidence of multi-organ dysfunction. Timely diagnosis and initiation of supportive care, including aggressive uid resuscitation and hemodynamic support, were followed by the implementation of blood puri cation therapies to enhance toxin elimination. Pharmacokinetic monitoring during therapy provided insights into the clearance rates and e ectiveness of hemodialysis in reducing BA levels. Serial measurements of plasma BA concentrations, along with clinical parameters such as renal function and acid-base status, guided therapeutic decision-making and optimization of blood puri cation protocols.

C ca c a a a c a

e clinical outcomes of BA poisoning can vary widely depending on the severity of exposure and the timeliness of intervention. In this case study, the patient's response to blood puri cation therapies was favorable, with improvement in metabolic acidosis and stabilization of organ function over the course of treatment. However, challenges such as the potential for rebound toxicity following discontinuation of therapy and the long-term consequences of BA exposure underscore the need for vigilant monitoring and supportive care.

C c

e pharmacokinetics and extracorporeal elimination of bongkrekic acid during blood puri cation therapies represent a critical aspect of its management in severe poisoning cases. is case study highlights the utility of hemodialysis and hemoperfusion in enhancing toxin clearance and improving clinical outcomes. Further research is warranted to elucidate optimal treatment strategies, re ne therapeutic protocols, and mitigate the risk of long-term sequelae associated with BA poisoning. Comprehensive management guidelines incorporating blood puri cation therapies are essential for healthcare providers to e ectively manage BA poisoning and improve patient survival. Blood puri cation therapies, including hemodialysis and hemoperfusion, proved e ective in enhancing BA elimination from circulation. Pharmacokinetic monitoring demonstrated a reduction in BA levels, correlating with improvements in metabolic parameters and organ function in the patient. ese ndings underscore the importance of early initiation and sustained application of blood puri cation therapies in severe BA poisoning cases. Moreover, this case study emphasizes the need for comprehensive management strategies that integrate supportive care, pharmacokinetic monitoring, and timely intervention to optimize patient outcomes. Future research should focus on re ning therapeutic protocols, investigating long-term e ects of BA poisoning, and exploring novel approaches for mitigating mitochondrial toxin-induced toxicity.

References

1. Selvam V (2003) Environmental classifcation of mangrove wetlands of India. Curr Sci 84: 757-765.
2. Krisfalusi-Gannon J, Ali W, Dellinger K, Robertson L, Brady TE (2018)The role of horseshoe crabs in the biomedical industry and recent trends impacting species sustainability. Front Mar Sci 5:185.
3. Arrieta MC, Arevalo A, Stiemsma L, Dimitriu P, Chico ME, et al. (2018) Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a no industrialized setting. J Allergy Clin Immunol 142: 424-434.
4. Stiemsma LT, Dimitriu PA, Thorson L, Russell S (2015) Early infancy microbial and metabolic alterations a fect risk of childhood asthma. Sci Transl Med 7:152-307.
5. Lorentzen HF, Ben feld T, Stisen S, Rahbek C (2020) COVID-19 is possibly a consequence of the anthropogenic biodiversity crisis and climate changes. Dan Med J 67: 20-25.
6. Nabeelah Bibi S, Fawzi MM, Gokhan Z, Rajesh J, Nadeem N, et al. (2019) Ethnopharmacology, phytochemistry, and global distribution of mangroves-A comprehensive review. Mar Drugs 17: 231.
7. Yuvaraj N, Kanmani P, Satishkumar R, Paari A, Arul V (2012)Seagrass as a potential source of natural antioxidant and anti-in fammatory agents. Pharm Biol 50: 458-467.
8. Danielsen F, Sørensen MK, Olwig MF, Burgess ND (2005) The Asian tsunami: a protective role for coastal vegetation. Science 310: 643.
9. Diogo-Filho A, Maia CP, Diogo DM, Diogo PM, Vasconcelos PM, et al. (2009) Estudo de vigilância epidemiológica da pro laxia do tromboembolismo venoso em especialidades cirúrgicas de um hospital universitário de nível terciário. J Infect Public Health 46: 9-14.
10. Paterson JC, McLachlin J (1954) Precipitating factors in venous thrombosis. Science 98: 96-102.